Brachytherapy
Volume 6, Issue 4 , Pages 272-279 , October 2007

Computed tomography–ultrasound fusion brachytherapy: Description and evolution of the technique

  • Donald B. Fuller

      Affiliations

    • Department of Radiation Oncology, Radiation Medical Group, Inc., San Diego, CA
    • Corresponding Author InformationCorresponding author. Department of Radiation Oncology, Radiation Medical Group, Inc., 2466 First Avenue, San Diego, CA 92101. Tel.: +1-619-230-0400; fax: +1-619-234-0414.
    • ,
  • Haoran Jin

      Affiliations

    • Western Cancer Center, Inc., San Diego, CA

Received 15 December 2006 ,Revised 10 August 2007 ,Accepted 21 August 2007.

References 

  1. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  2. Blasko JC, Grimm PD, Sylvester JE, et al. Related articles, Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839–850
  3. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  4. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005;173:1562–1566
  5. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  6. Stock RG, Stone NN, Dahlal M, et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Brachytherapy. 2002;1:83–89
  7. Merrick GS, Butler WM, Tollenaar BG, et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys. 2002;52:461–468
  8. Crook JM, Potters L, Stock RG, et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy. 2005;4:186–194
  9. Fuller DB, Jin H, Koziol JA, et al. CT-ultrasound fusion prostate brachytherapy: A dynamic dosimetry feedback and improvement method. A report of 54 consecutive cases. Brachytherapy. 2005;4:207–216
  10. Holm HH, Juul N, Pedersen JF, et al. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983;130:283–286
  11. D'Amico A, Cormack R, Kumar S, et al. Real-time magnetic resonance imaging-guided brachytherapy in the treatment of selected patients with clinically localized prostate cancer. J Endourol. 2000;14:367–370
  12. Stone NN, Stock RG. Brachytherapy for prostate cancer: Real-time three-dimensional interactive seed implantation. Tech Urol. 1995;1:72–80
  13. Potters L, Calguaru E, Thornton KB, et al. Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy. 2003;2:172–180
  14. Todor DA, Zaider M, Cohen GN, et al. Intraoperative dynamic dosimetry for prostate implants. Phys Med Biol. 2003;48:1153–1171
  15. Gong L, Cho PS, Han BH, et al. Ultrasonography and fluoroscopic fusion for prostate brachytherapy dosimetry. Int J Radiat Oncol Biol Phys. 2002;54:1322–1330

PII: S1538-4721(07)00242-5

doi: 10.1016/j.brachy.2007.08.003

Brachytherapy
Volume 6, Issue 4 , Pages 272-279 , October 2007

Article Tools

* Image Usage & Resolution